



Wnt signalling pathway in the serrated neoplastic pathway of the colorectum: possible roles and epigenetic regulatory mechanisms

Xiangsheng Fu, Li Li, Yan Peng

Department of Gastroenterology, Affiliated Hospital of Luzhou Medical College, Sichuan, China

Correspondence to

Dr Xiangsheng Fu, Department of Gastroenterology, Affiliated Hospital of Luzhou Medical College, Taiping Street 25#, Region Jiangyang, Luzhou, Sichuan 646000, China; drfuxs@gmail.com

Accepted 2 February 2012

ABSTRACT

The role of Wnt signalling in the serrated neoplastic pathway of colorectal tumourigenesis appears to be heterogeneous. Wnt pathway abnormalities contribute to the progression of at least a subset of traditional serrated adenomas of the colorectum, but may play a less active role in its pathogenesis compared with that in conventional adenoma-carcinoma. However, immunohistochemical studies of β -catenin in sessile serrated adenomas have shown wide variability, producing conflicting results on Wnt signalling activation in sessile serrated adenomas. DNA methylation, involving *APC*, *SFRPs* and mutated in colorectal cancer (*MCC*), may bridge the mutational gap of *APC* or β -catenin for activating Wnt signalling in serrated adenomas of the colorectum.

INTRODUCTION

Most colorectal cancers (CRCs) develop through a conventional adenoma (CA)—carcinoma sequence.^{1,2} However, recent increasing evidence suggests that 10%–20% of CRCs develop through the ‘serrated polyp-neoplasia pathway’.^{3–6} The recognition of this pathway in recent years has led to a paradigm shift in our understanding of the molecular basis of CRC and significant changes in clinical practice.⁷

Serrated polyps are histologically classified into hyperplastic polyps (HPs), traditional serrated adenomas (TSAs) and sessile serrated adenomas (SSAs).^{8,9} HPs are characterised by their small size (usually <0.5 cm), a predominantly left-sided location and generally regarded as non-neoplastic. Histologically, HPs have prominent serrations towards the luminal surface and crypts that narrow towards the muscularis mucosae (figure 1A). HPs are further classified as microvesicular HP, goblet cell HP, and mucin-depleted HP.¹⁰ Some data suggest that MVHP (especially right-sided) may be a precursor to more advanced SSAs.^{8,11,12}

TSAs were first described by Longacre and Fenoglio-Preiser¹³ in 1990 as serrated adenomas (SAs) that exhibit cytological dysplasia reminiscent of classical adenomas and a serrated architecture resembling HPs. TSAs are characterised by a predilection for the distal colon and rectum, apparent dysplasia, nuclear stratification and penicillate nuclei with abundant to moderate eosinophilic cytoplasm (figure 1B). Although TSAs were considered to be lesions of minor importance because of its low prevalence (2%–3.5%),⁷ recent reports claimed that TSAs have a higher growth rate than CAs, and that the subsequent cancer risk rate at least equals that of CAs.^{14,15}

In 1996, the term sessile serrated adenoma was introduced to refer to a subset of serrated lesions that cytologically resemble HPs but is distinguished from HPs on the basis of crypt dilation, branching and horizontal spreading (figure 1C, D).¹⁶ Unlike HPs, SSAs are characterised by a larger size, a predominantly right-sided location and the neoplastic potential. However, histopathological diagnosis of SSAs may be difficult, as they closely resemble HPs.^{17,18} The concept of SSAs was reintroduced in 2003 and were accounted to represent 18%–22% of serrated polyps.^{8,19} With the growing evidence of malignant change of SSA in epidemiological backgrounds, SSA has been considered to be the precursor of some microsatellite instability (MSI)-high carcinomas of the proximal colon.⁹ Some researchers concluded that SSAs were high-risk lesions, with 15% of the SSA patients developing subsequent CRCs or adenomas with high-grade dysplasia.²⁰ Furthermore, there is evidence that the neoplastic progression within this pathway is faster than within the classical adenoma-carcinoma sequence.^{14,21} However, the details of the molecular mechanism of stepwise progression from SSA to early invasive carcinoma remain unclear.


It is well known that Wnt signalling pathway involving β -catenin plays a critical role in colorectal carcinogenesis (figure 2).^{22,23} β -Catenin and its regulators, such as adenomatous polyposis coli (*APC*), is well studied in CAs and related carcinomas. However, the published data on Wnt pathway activation in SAs (including TSAs and SSAs) are controversial.^{24–28}

The purpose of this review is to discuss the possible role and regulatory mechanisms of Wnt signalling pathway in the development and progression of serrated polyps.

WNT SIGNALLING PATHWAY MAY PLAY A LESS ACTIVE ROLE IN THE PATHOGENESIS OF A SUBSET OF TSAS

Activation of the Wnt signalling pathway in CRC occurs almost invariably through mutation of the two key molecules: *APC* and β -catenin (*CTNNB1*).²⁹ Up to 80% of CRCs have *APC* mutations, whereas 10% of CRCs have β -catenin mutations.²⁹ An important function of the *APC* protein is to form a complex with the key effector β -catenin. Loss of *APC* function leads to translocation of β -catenin from the lateral cell membrane to the nucleus, where it promotes the transcription of multiple genes involved in tumour growth and invasion.³⁰

Figure 1 Histological features of serrated polyps. (A) Hyperplastic polyp: The serrations of the epithelium are confined to the upper half of the crypts, and the numbers of goblet cells are decreased relative to the normal mucosa. (B) Traditional serrated adenoma: This exophytic polyp shows serrated epithelial changes in association with cytoplasmic eosinophilia, nuclear enlargement and crowding. (C,D) Sessile serrated adenoma: In contrast to the hyperplastic polyp shown in A, the architecture of the crypts is distorted, seen as basal crypt dilatation (arrows) and crypt branching. H&E staining.



Although aberrant activation of Wnt signalling is a prerequisite for the initiation of most CRCs,²⁹ its role in TSAs is still controversial.

Some studies report a high incidence of *APC* gene mutation/loss of heterozygosity (LOH) in TSAs. Hiyama and colleagues²⁵ demonstrated *APC* mutation in 40% (2/5) of TSAs. In Matsumoto's study,³¹ 3/3 TSAs with familial adenomatous polyposis had germline *APC* mutation. In another study, LOH of *APC* was seen in 20% (7/35) of TSAs.³² However, most of these studies were limited by their small sample sizes.

Not all molecular studies have shown consistent findings. Sawyer *et al*³³ reported that *APC* mutations occurred in 12.8%

(5/39) of TSAs. In a study by Dehari *et al*,²⁷ *APC* mutations were detected in 3.8% (1/26) of TSAs, and in none of the four adenocarcinomas with TSAs, but were detected in 66.7% (8/12) of tubular adenomas and in 50% (4/8) of adenocarcinomas with tubular adenomas. Uchida and colleagues²⁶ found that 37.0% (10/27) of CAs showed somatic mutations of *APC* but no *APC* mutation was identified in 12 TSAs. In our previous study,³⁴ the frequency of *APC* gene mutation in TSAs (8.3%, 1/12) was significantly lower than that in CAs (56.3%, 9/16) and CRCs (50.0%, 7/14). These studies looking for *APC* mutations in TSAs have shown a low rate of detection, relative to the 50%–63% reported in CAs.³⁵

Sawyer *et al*³³ argued that *APC* mutations in these studies were likely to be underestimated because of poor quality of DNA retrieved from the archival material. However, we noticed that most of these studies had DNA from paraffin tissue sections of CAs as controls, which showed a high frequency of *APC* mutations. Moreover, even 3/3 TSAs had germline *APC* mutations in the study by Matsumoto *et al*,³¹ these mutations had been shown to cluster at the proximal exons 9 and at the distal 3' end of exon 15. It is reported that these mutations do not significantly affect the tumour-suppressor function of *APC*,^{36,37} suggesting that TSA of familial adenomatous polyposis may be a phenotype associated with less impaired *APC* function, although this study was limited by its very small sample size. Indeed, our previous study found that expression of *APC* protein in TSAs was higher than that in CAs, although the difference was not statistically significant.³⁴ These findings suggest that *APC*'s function in TSAs is less likely to be impaired compared with that in CA–carcinoma sequence.

Previously published results of β -catenin expression in TSAs had shown mixed findings. For instance, in a study by Jiao *et al*²⁴ in 2008, nuclear β -catenin positive cells were found in all TSAs (43 cases), but there was no significant difference in nuclear β -catenin positive rates between TSAs (30%) and CAs (30%).²⁴ In another study, Oh *et al*³⁸ also noted a relatively high frequency of positivity for β -catenin in TSAs (61%, 14/23).




Figure 2 A canonical Wnt signalling pathway. In the absence of Wnt signal, β -catenin is recruited into the APC/Axin/GSK3 β /CK destruction complex and phosphorylated by GSK3 β . The hyperphosphorylated β -catenin is targeted for degradation by the proteasome. Binding of Wnt ligand to a Frizzled/LRP-5/6 receptor complex, leading to the inhibition of APC/Axin/GSK3 β /CK-mediated β -catenin degradation. Stabilised β -catenin forms a transcriptional complex with Tcf/lef and activates downstream targets such as c-myc.

However, contradictory results have been reported by other investigators. Sawyer *et al*³³ evaluated β -catenin expression in 39 TSAs and found that only 12.8% (5/39) of TSAs showed nuclear β -catenin staining and 1/39 showed β -catenin mutation. Yamamoto *et al*²⁸ reported that widespread or focal nuclear β -catenin expression was demonstrated in 7% of TSAs (3/45), relative to 61% of CAs (43/71). Cytoplasmic immunostaining for β -catenin was demonstrated in 16% of TSAs (7/45) relative to 77% of CAs (55/71). No mutation in exon 3 of β -catenin was found in TSAs, while 7% of CAs (5/71) had β -catenin mutations. On the basis of these results, Yamamoto *et al*²⁸ concluded that intracellular localisation of β -catenin may not be associated with an early event of the tumour progression in most TSAs. However, Yachida *et al*³⁹ reviewed the immunostaining results presented in that paper, and argued that the figure indicated scattered positive nuclear labelling (not negative staining, as the authors pointed out).

In our previous study in 2009,³⁴ nuclear expression of β -catenin was not seen in any of the TSAs (12 cases). Cytoplasmic accumulation of β -catenin was demonstrated in 41.7% (5/12) of TSAs, relative to 68.6% (11/16) of CAs. No β -catenin mutation was detected in any of the 12 TSAs. In our more recent study in 2011,⁴⁰ nuclear labelling of β -catenin was detected in 19.6% of CAs (51 cases), but in none of the TSAs (37 cases). Cytoplasmic accumulation of β -catenin was found in 21.6% of TSAs, significantly lower than that in CAs (60.8%).

Although conflicting results exist, Wnt pathway abnormalities (involving changes in APC/ β -catenin) may contribute to the progression of at least a subset of TSAs of the colorectum. However, it is worth noting that there seems to be a trend that frequency of Wnt signalling abnormality in TSAs is lower than that in CAs, raising the possibility that the Wnt pathway may play a less active role in the pathogenesis of a certain proportion of TSAs.

CONFLICTING RESULTS ON ACTIVATION OF THE WNT SIGNALLING PATHWAY IN SSAS

The published data on Wnt pathway activation in SSAs are more conflicting. In a study by Wu *et al*,⁴¹ the authors surprisingly found that predominant nuclear labelling for β -catenin was noted in 9/22 SSAs (41%) but in none of the HPs. In all SSAs with nuclear labelling, membranous labelling was significantly decreased. They expanded upon this observation of β -catenin expression in a larger set of serrated polyps of the colorectum.³⁹ Immunolabelling for β -catenin confirmed the presence of nuclear accumulation in 35/54 (67%) SSAs, compared with 0/12 HPs. Furthermore, nuclear β -catenin labelling was seen in 8/27 (29%) SSAs without dysplasia, but in 27/27 (100%) SSAs with dysplasia. Molecular study revealed that aberrant nuclear labelling of β -catenin occurred in a background of *BRAF* activation.³⁹ Their findings suggest that aberrant Wnt signalling has a role in the development of a subset of SSAs and nuclear accumulation of β -catenin may be closely related to the early progression of SSAs.

The results from Sandmeier *et al*⁴² showed that abnormal β -catenin expression (loss of membranous β -catenin expression and nuclear β -catenin accumulation) was present in 37.5% (6/16) of SSAs, but not significantly different from 50.0% (6/12) of HPs. By contrast, in a study by Joo *et al*,⁴³ nuclear β -catenin staining was observed in 0% of SSAs. However, this study was limited by its small sample size ($n = 10$). In another study by Fujita *et al*,⁴⁴ no nuclear β -catenin expression was seen in 53 SSAs, although nuclear accumulation of β -catenin was observed in 50% (6/12) of

SSAs with neoplastic progression (SSANs, including intra-epithelial high-grade dysplasia and submucosal invasive carcinoma). These results are consistent with our previous study showing that nuclear labelling of β -catenin was detected in none of the SSAs and HPs tested.⁴⁰ These results indicate that Wnt pathway activation, seen as nuclear labelling for β -catenin, is unlikely to contribute to tumourigenesis in most SSAs.

Remarkably, these immunohistochemical studies of β -catenin in SSAs have shown wide variability in terms of proportion with nuclear staining, from 0% to 100%. Many reasons may contribute to these differing results, including intrinsic tumour heterogeneity, different stages of adenomas, small sample size, differences in antigen retrieval, antibodies and staining procedures used by each laboratory and different evaluations of immunostaining with varying degrees of sensitivity. Especially, conclusive studies of the Wnt signalling pathway in SSAs have been limited by the heterogeneity of SSAs classified in this category. Diagnostic criteria and nomenclature for these lesions are inconsistent and partly confusing.^{18 45} Therefore, some SSAs are still misdiagnosed and wrongly categorised, which may lead to differing results. Fortunately, a standardised diagnostic nomenclature of different serrated polyps was formulated in 2010,⁴⁵ meriting future research and clinical management of serrated polyps.

EPIGENETIC MECHANISMS IN ACTIVATING WNT SIGNALLING OF THE SERRATED NEOPLASTIC PATHWAY

Activating mutations in *CTNNB1* and *APC* are a common feature of CA–carcinoma sequence. Up to 80% of CRCs have *APC* mutations, whereas 10% of CRCs have β -catenin mutations.²⁹ However, most studies reported infrequent *APC* mutations in TSAs compared with that in CAs.^{26 27 33 34} MSI is classically a feature of TSAs that appear to distinguish them from CAs.^{33 46 47} It is reported that activating mutations in *CTNNB1*, not *APC* genetic inactivation, are frequent features of MSI CRCs that similarly cause stabilisation of β -catenin.^{48 49} However, activating mutations in *CTNNB1* is seldom seen in TSAs.^{28 33 34} Yachida and colleagues³⁹ also found no mutations in *CTNNB1* as a mechanism for Wnt activation, although they noted frequent β -catenin nuclear labelling in SSAs.

These results suggest that nuclear accumulation of β -catenin may also occur in the absence of mutations in the *APC*/ β -catenin pathway.³³ Previous studies have revealed that DNA methylation could provide an alternative mechanism to gene mutation for silencing *APC*.^{50–52} Moreover, Suzuki *et al*⁵³ provided compelling evidence of the Wnt pathway activation in CRC cell lines by hypermethylation of the Wnt pathway antagonists *SFRP1*, *SFRP2* and *SFRP5*. Indeed, a high frequency of DNA methylation is common in SAs and may play an important role in their pathogenesis.^{3 54–56} Thus, it is conceivable that DNA methylation could bridge the mutational gap of *APC* or *CTNNB1* for activating Wnt signalling in SAs.³⁹ Dhir *et al*⁵⁷ reported that *SFRPs* (1, 2, 4 and 5) were methylated frequently in SSAs and SSAs with dysplasia, but infrequently in HPs, providing evidence that the Wnt signalling pathway may be activated by epigenetic mechanisms in SSAs. Our previous study has also shown that hypermethylation of *APC* promoter 1A, instead of mutations involving *APC* and β -catenin, contributed to moderate activation of Wnt signalling in a subset of TSAs.³⁴ Whether *APC* methylation also plays a role in tumourigenesis of SSA remains to be tested.

Recent studies have shown that mutated in colorectal cancer (MCC), a candidate tumour suppressor, can also interact with

Take-home messages

- ▶ Wnt pathway abnormalities contribute to the progression of a subset of TSAs, but may play a less active role compared to that in conventional adenoma-carcinoma sequence.
- ▶ The role of Wnt signaling in the progression of SSA is still controversial. Further studies are needed to clarify this issue.
- ▶ DNA methylation may bridge the mutational gap for activating Wnt signaling in the “serrated polyp-neoplasia pathway” of the colorectum.

β -catenin, block β -catenin/TCF/LEF DNA binding, and affect endogenous β -catenin localisation/levels.⁵⁸ Moreover, *MCC* methylation, associated with *BRAF* mutation, was more common in serrated polyps than in CAs.⁵⁹ Therefore, *MCC* inactivation by promoter methylation could be an initiating Wnt pathway-activating event in the serrated neoplasia pathway. Additional studies will be required to address this possibility.

Contributors XF drafted the paper. LL revised the manuscript. YP edited the paper. All three authors take responsibility for the content of the paper.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. **Morson B.** President's address. The polyp-cancer sequence in the large bowel. *Proc R Soc Med* 1974;**67**:451–7.
2. **Hill MJ,** Morson BC, Bussey HJ. Aetiology of adenoma–carcinoma sequence in large bowel. *Lancet* 1978;**1**:245–7.
3. **Grady WM.** CIMP and colon cancer gets more complicated. *Gut* 2007;**56**:1498–500.
4. **Goldstein NS.** Serrated pathway and APC (conventional)-type colorectal polyps: molecular-morphologic correlations, genetic pathways, and implications for classification. *Am J Clin Pathol* 2006;**125**:146–53.
5. **Jass JR.** Serrated route to colorectal cancer: back street or super highway? *J Pathol* 2001;**193**:283–5.
6. **Makinen MJ.** Colorectal serrated adenocarcinoma. *Histopathology* 2007;**50**:131–50.
7. **Leggett B,** Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. *Gastroenterology* 2010;**138**:2088–100.
8. **Torlakovic E,** Skovlund E, Snover DC, et al. Morphologic reappraisal of serrated colorectal polyps. *Am J Surg Pathol* 2003;**27**:65–81.
9. **Snover DC,** Jass JR, Fenoglio-Preiser C, et al. Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. *Am J Clin Pathol* 2005;**124**:380–91.
10. **Lauwers GY,** Chung DC. The serrated polyp comes of age. *Gastroenterology* 2006;**131**:1631–4.
11. **Kim KM,** Lee EJ, Ha S, et al. Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. *Am J Surg Pathol* 2011;**35**:1274–86.
12. **Snover DC.** Update on the serrated pathway to colorectal carcinoma. *Hum Pathol* 2011;**42**:1–10.
13. **Longacre TA,** Fenoglio-Preiser CM. Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia. *Am J Surg Pathol* 1990;**14**:524–37.
14. **Lazarus R,** Junttila OE, Karttunen TJ, et al. The risk of metachronous neoplasia in patients with serrated adenoma. *Am J Clin Pathol* 2005;**123**:349–59.
15. **Chandra A,** Sheikh AA, Cerar A, et al. Clinico-pathological aspects of colorectal serrated adenomas. *World J Gastroenterol* 2006;**12**:2770–2.
16. **Cunningham KS,** Riddell RH. Serrated mucosal lesions of the colorectum. *Curr Opin Gastroenterol* 2006;**22**:48–53.
17. **Farris AB,** Misdraji J, Srivastava A, et al. Sessile serrated adenoma: challenging discrimination from other serrated colonic polyps. *Am J Surg Pathol* 2008;**32**:30–5.
18. **Torlakovic EE,** Gomez JD, Driman DK, et al. Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). *Am J Surg Pathol* 2008;**32**:21–9.
19. **Goldstein NS,** Bhanot P, Odish E, et al. Hyperplastic-like colon polyps that preceded microsatellite-unstable adenocarcinomas. *Am J Clin Pathol* 2003;**119**:778–96.
20. **Lu FI,** van Niekerk de W, Owen D, et al. Longitudinal outcome study of sessile serrated adenomas of the colorectum: an increased risk for subsequent right-sided colorectal carcinoma. *Am J Surg Pathol* 2010;**34**:927–34.
21. **Goldstein NS.** Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases. *Am J Clin Pathol* 2006;**125**:132–45.
22. **Bienz M,** Clevers H. Linking colorectal cancer to Wnt signaling. *Cell* 2000;**103**:311–20.
23. **Sena P,** Saviano M, Monni S, et al. Subcellular localization of beta-catenin and APC proteins in colorectal preneoplastic and neoplastic lesions. *Cancer Lett* 2006;**241**:203–12.
24. **Jiao YF,** Nakamura S, Sugai T, et al. Serrated adenoma of the colorectum undergoes a proliferation versus differentiation process: new conceptual interpretation of morphogenesis. *Oncology* 2008;**74**:127–34.
25. **Hiyama T,** Yokozaki H, Shimamoto F, et al. Frequent p53 gene mutations in serrated adenomas of the colorectum. *J Pathol* 1998;**186**:131–9.
26. **Uchida H,** Ando H, Maruyama K, et al. Genetic alterations of mixed hyperplastic adenomatous polyps in the colon and rectum. *Jpn J Cancer Res* 1998;**89**:299–306.
27. **Dehari R.** Infrequent APC mutations in serrated adenoma. *Tohoku J Exp Med* 2001;**193**:181–6.
28. **Yamamoto T,** Konishi K, Yamochi T, et al. No major tumorigenic role for beta-catenin in serrated as opposed to conventional colorectal adenomas. *Br J Cancer* 2003;**89**:152–7.
29. **Schneikert J,** Behrens J. The canonical Wnt signalling pathway and its APC partner in colon cancer development. *Gut* 2007;**56**:417–25.
30. **Korinek V,** Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. *Science* 1997;**275**:1784–7.
31. **Matsumoto T,** Iida M, Kobori Y, et al. Serrated adenoma in familial adenomatous polyposis: relation to germline APC gene mutation. *Gut* 2002;**50**:402–4.
32. **Fogt F,** Brien T, Brown CA, et al. Genetic alterations in serrated adenomas: comparison to conventional adenomas and hyperplastic polyps. *Hum Pathol* 2002;**33**:87–91.
33. **Sawyer EJ,** Cerar A, Hanby AM, et al. Molecular characteristics of serrated adenomas of the colorectum. *Gut* 2002;**51**:200–6.
34. **Fu X,** Li J, Li K, et al. Hypermethylation of APC promoter 1A is associated with moderate activation of Wnt signalling pathway in a subset of colorectal serrated adenomas. *Histopathology* 2009;**55**:554–63.
35. **Miyoshi Y,** Ando H, Nagase H, et al. Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. *Proc Natl Acad Sci U S A* 1992;**89**:4452–6.
36. **Su LK,** Barnes CJ, Yao W, et al. Inactivation of germline mutant APC alleles by attenuated somatic mutations: a molecular genetic mechanism for attenuated familial adenomatous polyposis. *Am J Hum Genet* 2000;**67**:582–90.
37. **Friedl W,** Meuschel S, Caspari R, et al. Attenuated familial adenomatous polyposis due to a mutation in the 3' part of the APC gene. A clue for understanding the function of the APC protein. *Hum Genet* 1996;**97**:579–84.
38. **Oh K,** Redston M, Odze RD. Support for hMLH1 and MGMT silencing as a mechanism of tumorigenesis in the hyperplastic-adenoma-carcinoma (serrated) carcinogenic pathway in the colon. *Hum Pathol* 2005;**36**:101–11.
39. **Yachida S,** Mudali S, Martin SA, et al. Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. *Am J Surg Pathol* 2009;**33**:1823–32.
40. **Fu X,** Yang X, Chen K, et al. Retained cell-cell adhesion in serrated neoplastic pathway as opposed to conventional colorectal adenomas. *J Histochem Cytochem* 2011;**59**:158–66.
41. **Wu JM,** Montgomery EA, Iacobuzio-Donahue CA. Frequent beta-catenin nuclear labeling in sessile serrated polyps of the colorectum with neoplastic potential. *Am J Clin Pathol* 2008;**129**:416–23.
42. **Sandmeier D,** Benhattar J, Martin P, et al. Serrated polyps of the large intestine: a molecular study comparing sessile serrated adenomas and hyperplastic polyps. *Histopathology* 2009;**55**:206–13.
43. **Joo M,** Shahsafaie A, Odze RD. Paneth cell differentiation in colonic epithelial neoplasms: evidence for the role of the Apc/beta-catenin/Tcf pathway. *Hum Pathol* 2009;**40**:872–80.
44. **Fujita K,** Yamamoto H, Matsumoto T, et al. Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study. *Am J Surg Pathol* 2011;**35**:295–304.
45. **Aust DE,** Baretton GB. Serrated polyps of the colon and rectum (hyperplastic polyps, sessile serrated adenomas, traditional serrated adenomas, and mixed polyps)-proposal for diagnostic criteria. *Virchows Arch* 2010;**457**:291–7.
46. **Hawkins NJ,** Ward RL. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. *J Natl Cancer Inst* 2001;**93**:1307–13.
47. **Jass JR,** Biden KG, Cummings MC, et al. Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. *J Clin Pathol* 1999;**52**:455–60.
48. **Mirabelli-Primdahl L,** Gryfe R, Kim H, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. *Cancer Res* 1999;**59**:3346–51.
49. **Morin PJ,** Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. *Science* 1997;**275**:1787–90.
50. **Esteller M,** Sparks A, Toyota M, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. *Cancer Res* 2000;**60**:4366–71.
51. **Nathke IS.** The adenomatous polyposis coli protein: the Achilles heel of the gut epithelium. *Annu Rev Cell Dev Biol* 2004;**20**:337–66.

52. **Chen J**, Rocken C, Lofton-Day C, *et al.* Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis. *Carcinogenesis* 2005;**26**:37–43.
53. **Suzuki H**, Watkins DN, Jair KW, *et al.* Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. *Nat Genet* 2004;**36**:417–22.
54. **O'Brien MJ**, Yang S, Mack C, *et al.* Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. *Am J Surg Pathol* 2006;**30**:1491–501.
55. **Park SJ**, Rashid A, Lee JH, *et al.* Frequent CpG island methylation in serrated adenomas of the colorectum. *Am J Pathol* 2003;**162**:815–22.
56. **Dong SM**, Lee EJ, Jeon ES, *et al.* Progressive methylation during the serrated neoplasia pathway of the colorectum. *Mod Pathol* 2005;**18**:170–8.
57. **Dhir M**, Yachida S, Van Neste L, *et al.* Sessile serrated adenomas and classical adenomas: an epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract. *Int J Cancer*. Published Online First: 10 December 2010.
58. **Fukuyama R**, Nicalaita R, Ng KP, *et al.* Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription. *Oncogene* 2008;**27**:6044–55.
59. **Kohonen-Corish M**, Sigglekow N, Susanto J, *et al.* Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. *Oncogene* 2007;**26**:4435–41.